Read + Share
Nishimura T, Fujimoto H. PFS, OS or toxicity: What is the most important factor in the treatment of
EGFR-mutated lung cancer? Ann Oncol 2024 Oct 11:S0923-7534(24)04059-6. doi: 10.1016/j.annonc.2024.
PMID: 39396756
|
 |
|
Nishimura T, Fujimoto H. PFS, OS or toxicity: What is the most important factor in the treatment of
EGFR-mutated lung cancer? Ann Oncol 2024 Oct 11:S0923-7534(24)04059-6. doi: 10.1016/j.annonc.2024.
PMID: 39396756
|
|
|
|